GOVERNMENT OF NCT of DELHI
DEPARTMENT OF HEALTH & FAMILY WELFARE
IRDER
F No. PAISSSHFW/2021/Tocilizomab/CD-112648651/ 5°‘ fof Dated :13.5.2021
237-246
In order to streamline and systematize the distribution of Tocilizumab injections
to prevent the indiscriminate use of this injection and to establish a transparent, efficient
and time-bound system of distribution of this drug to the needy and hospitalized COVID-
19 patients on clinically approved evidence-based grounds and ethical principle of
distributive justice across Delhi, the competent authority has approved the constitution
of a 3 member ‘Technical Expert Committee (TEC) as follows:
1) Dr. Paeeeraenenee). as Chairman.
esia Branch, MAMC)
re prescribed to approve the distribution/supply of
pitals (Govt and Private) only for the treatment of
lospitals requiring Injection Tocilizumab for
ply to the Technical Experts Committee.
\nnexure-A) to be sent to the TEC through
cation without filled proforma or incomplete
meetings can be held on a
Il be evidence based clinically
distributive justice and
Scanned with CamScannervi. On recomm i
sitiGitoed peepee Of the TEC, the olo DGHS shall issue the drug to the
f CF, aha Baan, Government Hospital/institution concerned or the
e
/ Concerned (in this ae fepresentative of the Private Hospital
basis) as the case may be
vii. DGHS and all the
CFAsiStockists will ensure the issuance of drug on same day
nt and Private Hospital concemed. Respectively, All relevant records
‘by o/oDGHS.
v/Private hospital will submit report regarding usage of drug for
ponsibility of the Hospital Administration of the
ensure appropriate use of prescription medicine,
tion with health authorities and to keep proper
ment Agencies on special
(pz a
Ash
Raj Kumar
Spl. Secretary, (H&FW)
Scanned with CamScannerAnnexure- A
GOVERNMENT OF NCT of DELHI
DEPARTMENT OF HEALTH & FAMILY WELFARE
ni
2 nly @ multidisciplinary team or 3 members team consisting of physician
volved in COVID patient care (to be signed by at least two) can recommend
‘the use of Tocilizumab/Immunomodulator therapy.
followil meters have to be considered and recorded
Condition
Coexistent infection other than
COVID-19
PaO2/FiO2> 300 mm Hg; chronic
lucocorticoid use
H/o another ILG inhibitor in
resent admission.
| H/O severe allergic reactions to
onoclonal antibodies
<500 per MLiplatelets <
‘diverticulitis, IBD, or
iptomatic
inal tract condition that
canned with CamScannerPresently admitted in
(ODIMM/Year) is
found to be an eligible for Tocilizumab
Scanned with CamScanner